Halozyme Therapeutics Inc. Common Stock vs SK Hynix — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.59 (market cap $12.58B), while SK Hynix trades at $169.76 (market cap $891.31B). The key difference: SK Hynix is far larger — about 70.9× Halozyme Therapeutics Inc. Common Stock's market cap, and SK Hynix pays a 0.06% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and SK Hynix for 10 Days on average.
| HALO | SKHY | |
|---|---|---|
Market Cap | $12.58B | $891.31B |
Volume | 2,179,278 | 22,268,296 |
Sector | Health | Technology |
52-Week High | $115.22 | $198.63 |
52-Week Low | $61.63 | $126.79 |
Typical Hold Time | 1 Days | 10 Days |
Enterprise Value | $14.49B | $841.45B |
Dividend Yield | — | 0.06% |
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →SK hynix is a South Korean semiconductor company that manufactures memory products, including DRAM and NAND flash. Its high-bandwidth memory (HBM) products are designed for high-performance computing and AI applications.
Read more on SKHY →